2015/1 GaBI Journal Table of Contents

Contents

Editor’s Letter

Editor’s introduction to the initial issue of the fourth volume of GaBI Journal

Editorial

Biosimilars: patient and physician acceptability is the fifth hurdle to market competition

Letters to the Editor

Generic medicines policy in Qatar

Commentary

The EU regulatory approach to generics and biosimilars is essentially similar

Original Research

Payer and physician evidence and discount requirements for biosimilars in three Latin American countries

What pricing and reimbursement policies to use for off-patent biologicals? – Results from the EBE 2014 biological medicines policy survey

Review Article

The refinement of the super generic concept: semantic challenge for product re-innovation?

Perspective

Biosimilars for prescribers

Regulatory

Health Canada’s perspective on the clinical development of biosimilars and related scientific and regulatory challenges

Pharma News

Top developments in biosimilars during 2014

World News

Generics authorization – groundbreaking regulatory approach to closer international cooperation on the rise – IGDRP

Abstracted Scientific Content

Generics and off-patent biologicals for cancer treatment in developing countries

Source URL: https://gabi-journal.net/20151-gabi-journal-table-of-contents.html


Generics and Biosimilars Initiative (GaBI)
Tel: +32 474989572 | Fax: +32 14 583 048